Improvement of Pediatric Drug Development: Regulatory and Practical Frameworks

Area of Science:

• Pharmacology and Clinical Trials
• Pediatric Drug Development
• Regulatory Science

Background:

• Pediatric drug development is limited, leading to off-label prescribing and increased adverse events.
• Addressing the therapeutic orphan status of pediatric drugs requires improved development pathways.
• Current challenges include recruitment and ethical considerations in pediatric clinical trials.

Purpose of the Study:

• To assess the current status of pediatric drug development.
• To identify problems hindering pediatric drug development.
• To propose actions for improving drug development for pediatric conditions.

Main Methods:

• Analysis of Phase II/III and III pediatric clinical trials (2006-2014) from ClinicalTrials.gov.
• Calculation of a performance index for pediatric drug development.
• Comparison of pediatric clinical trial activity in Japan, the EU, and US before and after Japanese premiums (2010).
• Survey of EU Clinical Trials Register and EMA reports to assess the Paediatric Committee's impact.

Main Results:

• Japan's pediatric drug development significantly increased post-premiums, reaching EU levels.
• The EU Pediatric Regulation and Paediatric Committee stimulated pediatric clinical trials.
• EU clinical trial registrations for pediatric participants increased substantially post-regulation.
• The proportion of trials with approved Paediatric Investigation Plans in the EU rose above 15% after 2008.

Conclusions:

• Improved operational and regulatory frameworks are essential for incentivizing pediatric drug development.
• Technological advancements, EMR enhancements, and community engagement can improve participant recruitment.
• Enhanced collaboration among industry, government, academia, and communities is crucial.
• Adopting successful regulatory strategies and innovative trial tools can address the pediatric therapeutic orphan drug issue.